From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment [0.03%]
从临床到非临床结果的HIV治疗：经济和组织影响评估
Ferrario Lucrezia,Menzaghi Barbara,Rizzardini Giuliano et al.
Ferrario Lucrezia et al.
Objective: The aim of this study was to define the economic and organizational impacts related to a broader utilization of bictegravir/emtricitabine/alafenamide (BIC/FTC/TAF) in Italian clinical practice. ...
CMS's Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks [0.03%]
2023年CMS药物价格谈判计划患者聚焦听证会发言内容描述性分析报告
Julie A Patterson,Tyler D Wagner,Rayan K Salih et al.
Julie A Patterson et al.
Background: The US Centers for Medicare and Medicaid Services (CMS) held patient-focused listening sessions in Fall 2023 for each of the first ten drugs selected for the Inflation Reduction Act's (IRA) Drug Price Negotiat...
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment [0.03%]
一线治疗晚期或转移性肾细胞癌患者的不良事件成本分析
Yan Chen,Ella X Du,Manasvi Sundar et al.
Yan Chen et al.
Aim: This study evaluated costs associated with adverse events (AEs) in previously untreated real-world patients with advanced renal cell carcinoma (aRCC) in the USA. ...
Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis [0.03%]
英国NHS视角下的数字同意与纸质同意的微成本分析
Rachel Houten,Mohammad Iqbal Hussain,Antony P Martin et al.
Rachel Houten et al.
Background: The paper-based consent pathway can be associated with missing information, error, and inadequate patient comprehension. Digital consent addresses some of these limitations. However, limited research has been ...
Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years [0.03%]
新一代三种药物洗脱支架在生物工程随机评估中的成本效益：第3年结果
Eline H Ploumen,Martijn J Oude Wolcherink,Rosaly A Buiten et al.
Eline H Ploumen et al.
Background and objective: Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised...
Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy [0.03%]
意大利输血依赖型β地中海贫血和反复血管阻塞危象型镰状细胞病的管理相关的死亡率、临床并发症和卫生资源利用情况
Chuka Udeze,Melania Dovizio,Chiara Veronesi et al.
Chuka Udeze et al.
Objective: To examine the clinical burden and healthcare resource utilization (HCRU) among patients with transfusion-dependent β-thalassemia (TDT) and patients with sickle cell disease (SCD) with recurrent vaso-occlusive...
Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing [0.03%]
多癌症早期检测(MCED)与常规癌症筛查相结合的系统动力学模型开发及可行性测试
Mussab Fagery,Hadi A Khorshidi,Stephen Q Wong et al.
Mussab Fagery et al.
Background: Cancer screening plays a critical role in early disease detection and improving outcomes. In Australia, established screening protocols for colorectal, breast and cervical cancer have significantly contributed...
Divya Patil,Emily F Gorman,T Joseph Mattingly nd
Divya Patil
Background: Huntington's disease (HD) is associated with significant financial burden for patients and payers. The objective was to identify and quantify costs of HD by stage of disease progression. ...
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study [0.03%]
在加拿大溃疡性结肠炎和克罗恩病中将 vedolizumab 用作一线生物制剂的性价比分析：基于真实世界证据的 EVOLVE 研究结果
Aren Fischer,Stephen Mac,Erica Stivelman Freiman et al.
Aren Fischer et al.
Introduction: Vedolizumab is a gut-selective anti-lymphocyte trafficking biologic indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in Canada...
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA [0.03%]
呋喹替尼在美国治疗难治性转移性结直肠癌的 cost-effectiveness 分析
Dong-Won Kang,Patricio B Lynn,Li Wang et al.
Dong-Won Kang et al.
Background: The FRESCO-2 trial established the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. However, its cost-effectiveness in the US context is not well documented. ...